Mr. Carlucci has been a Managing Director of Carlyle
since 1989, Chairman since 1993 and Chairman
Emeritus since January 2003. Mr. Carlucci was
Secretary of Defense from November 1987 through
January 1989, following his service as Assistant to
the President for National Security Affairs under
President Reagan. Before serving in these positions,
Mr. Carlucci was Chairman and CEO of Sears World
Trade, a business he joined in 1983. Mr. Carlucci
preceded his affiliation with Sears World Trade,
Inc. with a career in government service, which
included Deputy Secretary of Defense (1980-82),
Deputy Director of Central Intelligence (1978-80),
Ambassador to Portugal (1975-78), Under Secretary of
Health Education and Welfare (1973-75), Deputy
Director of OMB (1970-72), and Director of the
Office of Economic Opportunity (1969). Mr. Carlucci
was a Foreign Service Officer from 1956 to 1980 and
he served as an officer in the U.S. Navy from 1952
to 1954.
Mr. Carlucci is Chairman Emeritus of Nortel Networks
and the US-Taiwan Business Council and the Chairman
of the Neurogen Corporation Board of Directors.
Additionally, Mr. Carlucci serves as a member on the
following corporate boards: SunResorts, Ltd., N.V.;
Texas Biotechnology Corporation and United Defense
L.P.
Among Mr. Carlucci's awards and honours are the
Herbert Roback Memorial Award, 1989; George C.
Marshall Award, 1989; Honorary Doctor of Laws
Degree, University of Scranton, 1989; Woodrow Wilson
Award, 1988; James Forrestal Award, 1988;
Presidential Citizens Award, 1983; National
Intelligence Distinguished Service Medal, 1981;
Distinguished Intelligence Medal, 1981; Defense
Department Distinguished Civilian Service Award,
1977; Health, Education and Welfare Distinguished
Civilian Service Award, 1975; and State Department
Superior Service Award, 1971.
Mr. Carlucci, born October 18, 1930, graduated from
Princeton University and attended Harvard Business
School. He is married to the former Marcia Myers,
and has three children: Frank, Karen and Kristin.
Dr. Philip Schein is widely
regarded as a leading international authority in the
treatment of cancer. He currently serves as a
Visiting Professor in Cancer Pharmacology, Oxford
University, and President of The Schein Group, which
provides consultative services to the pharmaceutical
industry. He is a former President of the American
Society of Clinical Oncology, Chairman of the FDA
Oncology Drugs Advisory Committee and a member of
the National Cancer Advisory Board. His prior appointments were at the
National Cancer Institute, Bethesda, Maryland where
he served as Senior Investigator and Head of the
Clinical Pharmacology Section of the Medicine Branch
and at Georgetown University School of Medicine in
Washington, DC, as Professor of Medicine and
Pharmacology and Scientific Director of the Vincent
T. Lombardi Cancer Research Center. He has also
served as Vice President of Worldwide Clinical
Research and Development, and Director of the
Laboratory of Molecular Oncology, SmithKline &
French Laboratories, where he had responsibility for
all SK&F clinical research and development
activities. In 1987 he founded US Bioscience, a
pharmaceutical company focused in the field of
oncology, where he served as Chairman and CEO of
U.S. Bioscience and took three products, Ethyol,
Neutrexin and Hexalen, through development and
regulatory approval in the US, Europe, Canada and
other countries.
